This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Nurix Stock Up 29% in a Month: Here's What You Should Know
by Zacks Equity Research
NRIX rallies on its collaboration with Roche for bexobrutideg, featuring a $700 million upfront payment and potential milestone payouts of up to $2.3 billion.
NRIXNegative Net Change SNYNegative Net Change RHHBYNegative Net Change GILDNegative Net Change
biotechs
IONS Out-Licenses ex-U.S. Rights for Rare Neurology Drug to Recordati
by Zacks Equity Research
Ionis grants Recordati ex-U.S. rights to zilganersen for Alexander disease while retaining U.S. commercialization and securing upfront and royalty payments.
IONSNegative Net Change IMCRNegative Net Change INDVNegative Net Change
biotechs medical pharmaceuticals
Here's Why You Should Add Kiniksa Stock to Your Portfolio Now
by Zacks Equity Research
KNSA's Arcalyst sales continue to grow as raised 2026 revenue guidance and an expanding IL-1 pipeline reinforce Kiniksa's growth strategy.
KNSANegative Net Change REGNNegative Net Change LQDANegative Net Change IMCRNegative Net Change
biotechs
Kymera Jumps 17% on Early Enrollment Completion in Skin Disease Study
by Zacks Equity Research
KYMR stock soars 17% as investor optimism was lifted following early enrollment completion in mid-stage AD study, moving KT-621 top-line data to year-end 2026.
KYMRPositive Net Change LQDANegative Net Change IMCRNegative Net Change INDVNegative Net Change
biotechnology biotechs medical pharmaceuticals
BAYRY Stock Surges 17% After Supreme Court Roundup Ruling
by Zacks Equity Research
Bayer shares jump 17% after a Supreme Court ruling on Roundup litigation that could significantly reduce warning-based claims and litigation costs.
BAYRYNegative Net Change REGNNegative Net Change JNJNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Biogen's New Drugs Revive Growth Amid Legacy Sales Slump?
by Kinjel Shah
Biogen is betting on Leqembi, Skyclarys and Zurzuvae to offset declining legacy drug sales, but replacing lost revenues may take time.
NVSNegative Net Change BIIBPositive Net Change SUPNNegative Net Change PTCTNegative Net Change
biotechs
FDA Expands IONS' Tryngolza Label to Treat Severe Hypertriglyceridemia
by Zacks Equity Research
Ionis wins FDA approval to expand Tryngolza to severe hypertriglyceridemia, opening a broader market as the first approved treatment for the condition.
IONSNegative Net Change AZNNegative Net Change GSKPositive Net Change BIIBPositive Net Change
biotechs medical pharmaceuticals
Here's Why You Should Add ANIX Stock to Your Portfolio Now
by Zacks Equity Research
Anixa advances cancer vaccines and CAR-T therapies, supported by positive early data, a planned phase II study and expanding intellectual property protection.
ANIXNegative Net Change AMRNNegative Net Change LQDANegative Net Change IMCRNegative Net Change
biotechs
ABSI Soars 36% on Positive Interim Update From Phase I Hair Loss Study
by Zacks Equity Research
Absci stock jumps 36% as interim phase I hair loss study data show ABS-201 is well tolerated and pharmacokinetics support the potential for infrequent dosing.
ABSINegative Net Change LQDANegative Net Change IMCRNegative Net Change KVUEPositive Net Change
biotechnology biotechs medical pharmaceuticals
Gilead's Breast Cancer Drug Trodelvy Wins FDA Nod for Expanded Use
by Zacks Equity Research
GILD wins FDA approval to expand Trodelvy into first-line metastatic triple-negative breast cancer, opening a broader treatment opportunity.
GILDNegative Net Change MRKNegative Net Change LQDANegative Net Change IMCRNegative Net Change
biotechnology biotechs medical pharmaceuticals